vs
Amphastar Pharmaceuticals, Inc.（AMPH）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是COMSCORE, INC.的2.0倍（$183.1M vs $93.5M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 3.2%，领先10.1%），COMSCORE, INC.同比增速更快（-1.5% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $2.9M），过去两年COMSCORE, INC.的营收复合增速更高（3.8% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
AMPH vs SCOR — 直观对比
营收规模更大
AMPH
是对方的2.0倍
$93.5M
营收增速更快
SCOR
高出0.3%
-1.8%
净利率更高
AMPH
高出10.1%
3.2%
自由现金流更多
AMPH
多$21.7M
$2.9M
两年增速更快
SCOR
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $93.5M |
| 净利润 | $24.4M | $3.0M |
| 毛利率 | 46.8% | 41.0% |
| 营业利润率 | 19.4% | 7.0% |
| 净利率 | 13.3% | 3.2% |
| 营收同比 | -1.8% | -1.5% |
| 净利润同比 | -35.7% | -3.7% |
| 每股收益（稀释后） | $0.51 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHSCOR
| Q4 25 | $183.1M | $93.5M | ||
| Q3 25 | $191.8M | $88.9M | ||
| Q2 25 | $174.4M | $89.4M | ||
| Q1 25 | $170.5M | $85.7M | ||
| Q4 24 | $186.5M | $94.9M | ||
| Q3 24 | $191.2M | $88.5M | ||
| Q2 24 | $182.4M | $85.8M | ||
| Q1 24 | $171.8M | $86.8M |
净利润AMPHSCOR
| Q4 25 | $24.4M | $3.0M | ||
| Q3 25 | $17.4M | $453.0K | ||
| Q2 25 | $31.0M | $-9.5M | ||
| Q1 25 | $25.3M | $-4.0M | ||
| Q4 24 | $38.0M | $3.1M | ||
| Q3 24 | $40.4M | $-60.6M | ||
| Q2 24 | $37.9M | $-1.7M | ||
| Q1 24 | $43.2M | $-1.1M |
毛利率AMPHSCOR
| Q4 25 | 46.8% | 41.0% | ||
| Q3 25 | 51.4% | 40.6% | ||
| Q2 25 | 49.6% | 40.6% | ||
| Q1 25 | 50.0% | 39.6% | ||
| Q4 24 | 46.5% | 42.4% | ||
| Q3 24 | 53.3% | 41.2% | ||
| Q2 24 | 52.2% | 39.5% | ||
| Q1 24 | 52.4% | 42.3% |
营业利润率AMPHSCOR
| Q4 25 | 19.4% | 7.0% | ||
| Q3 25 | 13.2% | 1.9% | ||
| Q2 25 | 24.2% | -1.9% | ||
| Q1 25 | 21.9% | -2.4% | ||
| Q4 24 | 24.2% | 4.1% | ||
| Q3 24 | 29.8% | -67.4% | ||
| Q2 24 | 30.3% | -2.2% | ||
| Q1 24 | 27.9% | -2.2% |
净利率AMPHSCOR
| Q4 25 | 13.3% | 3.2% | ||
| Q3 25 | 9.0% | 0.5% | ||
| Q2 25 | 17.8% | -10.6% | ||
| Q1 25 | 14.8% | -4.7% | ||
| Q4 24 | 20.4% | 3.3% | ||
| Q3 24 | 21.1% | -68.5% | ||
| Q2 24 | 20.8% | -2.0% | ||
| Q1 24 | 25.1% | -1.2% |
每股收益（稀释后）AMPHSCOR
| Q4 25 | $0.51 | $9.50 | ||
| Q3 25 | $0.37 | $-0.86 | ||
| Q2 25 | $0.64 | $-2.73 | ||
| Q1 25 | $0.51 | $-1.66 | ||
| Q4 24 | $0.74 | $-0.47 | ||
| Q3 24 | $0.78 | $-12.79 | ||
| Q2 24 | $0.73 | $-1.19 | ||
| Q1 24 | $0.81 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $23.6M |
| 总债务越低越好 | $608.7M | $41.5M |
| 股东权益账面价值 | $788.8M | $111.4M |
| 总资产 | $1.6B | $407.7M |
| 负债/权益比越低杠杆越低 | 0.77× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资AMPHSCOR
| Q4 25 | $282.8M | $23.6M | ||
| Q3 25 | $276.2M | $26.7M | ||
| Q2 25 | $231.8M | $26.0M | ||
| Q1 25 | $236.9M | $31.0M | ||
| Q4 24 | $221.6M | $29.9M | ||
| Q3 24 | $250.5M | $20.0M | ||
| Q2 24 | $217.8M | $14.7M | ||
| Q1 24 | $289.6M | $18.7M |
总债务AMPHSCOR
| Q4 25 | $608.7M | $41.5M | ||
| Q3 25 | $608.6M | $41.4M | ||
| Q2 25 | $607.7M | $41.3M | ||
| Q1 25 | $603.9M | $41.3M | ||
| Q4 24 | $601.6M | $41.2M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHSCOR
| Q4 25 | $788.8M | $111.4M | ||
| Q3 25 | $776.7M | $-26.3M | ||
| Q2 25 | $757.5M | $-21.7M | ||
| Q1 25 | $751.3M | $-13.5M | ||
| Q4 24 | $732.3M | $-8.3M | ||
| Q3 24 | $727.7M | $-2.7M | ||
| Q2 24 | $713.3M | $45.8M | ||
| Q1 24 | $672.4M | $51.4M |
总资产AMPHSCOR
| Q4 25 | $1.6B | $407.7M | ||
| Q3 25 | $1.7B | $406.9M | ||
| Q2 25 | $1.6B | $415.9M | ||
| Q1 25 | $1.6B | $421.5M | ||
| Q4 24 | $1.6B | $430.2M | ||
| Q3 24 | $1.5B | $412.5M | ||
| Q2 24 | $1.5B | $474.1M | ||
| Q1 24 | $1.6B | $477.7M |
负债/权益比AMPHSCOR
| Q4 25 | 0.77× | 0.37× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $2.9M |
| 自由现金流率自由现金流/营收 | 13.4% | 3.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.35× | 1.07× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $21.8M |
8季度趋势，按日历期对齐
经营现金流AMPHSCOR
| Q4 25 | $32.9M | $3.2M | ||
| Q3 25 | $52.6M | $9.5M | ||
| Q2 25 | $35.6M | $932.0K | ||
| Q1 25 | $35.1M | $9.1M | ||
| Q4 24 | $29.0M | $-10.0M | ||
| Q3 24 | $60.0M | $12.5M | ||
| Q2 24 | $69.1M | $8.7M | ||
| Q1 24 | $55.3M | $6.9M |
自由现金流AMPHSCOR
| Q4 25 | $24.6M | $2.9M | ||
| Q3 25 | $47.2M | $9.4M | ||
| Q2 25 | $25.0M | $787.0K | ||
| Q1 25 | $24.4M | $8.7M | ||
| Q4 24 | $16.6M | $-10.3M | ||
| Q3 24 | $46.2M | $12.4M | ||
| Q2 24 | $63.1M | $8.5M | ||
| Q1 24 | $46.5M | $6.6M |
自由现金流率AMPHSCOR
| Q4 25 | 13.4% | 3.1% | ||
| Q3 25 | 24.6% | 10.5% | ||
| Q2 25 | 14.3% | 0.9% | ||
| Q1 25 | 14.3% | 10.1% | ||
| Q4 24 | 8.9% | -10.8% | ||
| Q3 24 | 24.1% | 14.0% | ||
| Q2 24 | 34.6% | 10.0% | ||
| Q1 24 | 27.1% | 7.6% |
资本支出强度AMPHSCOR
| Q4 25 | 4.5% | 0.3% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.4% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.2% | ||
| Q1 24 | 5.1% | 0.3% |
现金转化率AMPHSCOR
| Q4 25 | 1.35× | 1.07× | ||
| Q3 25 | 3.03× | 20.96× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | -3.19× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
